Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 198.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 681,012 shares of the company's stock after purchasing an additional 452,627 shares during the period. Nuveen Asset Management LLC owned approximately 0.86% of Viridian Therapeutics worth $13,055,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of VRDN. Voya Investment Management LLC lifted its stake in shares of Viridian Therapeutics by 5.1% during the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after acquiring an additional 1,038 shares during the last quarter. Tudor Investment Corp ET AL lifted its stake in shares of Viridian Therapeutics by 3.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after acquiring an additional 1,106 shares during the last quarter. R Squared Ltd bought a new stake in shares of Viridian Therapeutics during the 4th quarter worth approximately $26,000. Summit Investment Advisors Inc. lifted its stake in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after acquiring an additional 1,516 shares during the last quarter. Finally, AlphaQuest LLC lifted its stake in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have commented on VRDN shares. The Goldman Sachs Group reduced their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. JMP Securities dropped their target price on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC restated a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. Royal Bank of Canada dropped their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, HC Wainwright restated a "buy" rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $36.70.

Viridian Therapeutics Stock Performance

VRDN traded down $0.18 on Friday, reaching $13.79. 768,725 shares of the stock were exchanged, compared to its average volume of 1,192,614. The company's 50-day moving average price is $13.02 and its 200 day moving average price is $16.45. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The firm has a market capitalization of $1.13 billion, a PE ratio of -3.20 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. The business's quarterly revenue was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.